Dermapharm Holding Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Hans-Georg Feldmeier

Chief executive officer

€1.4m

Total compensation

CEO salary percentage	59.7%
CEO tenure	7.1yrs
CEO ownership	n/a
Management average tenure	2yrs
Board average tenure	7.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Hans-Georg Feldmeier's remuneration changed compared to Dermapharm Holding's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	€83m
Mar 31 2024	n/a	n/a	€57m
Dec 31 2023	€1m	€821k	€62m
Sep 30 2023	n/a	n/a	€95m
Jun 30 2023	n/a	n/a	€123m
Mar 31 2023	n/a	n/a	€146m
Dec 31 2022	€1m	€800k	€134m
Sep 30 2022	n/a	n/a	€176m
Jun 30 2022	n/a	n/a	€185m
Mar 31 2022	n/a	n/a	€211m
Dec 31 2021	€1m	€800k	€210m
Sep 30 2021	n/a	n/a	€162m
Jun 30 2021	n/a	n/a	€123m
Mar 31 2021	n/a	n/a	€95m
Dec 31 2020	€736k	€411k	€86m

Compensation vs Market: Hans-Georg's total compensation ($USD1.54M) is below average for companies of similar size in the UK market ($USD2.24M).

Compensation vs Earnings: Hans-Georg's compensation has been consistent with company performance over the past year.

CEO

Hans-Georg Feldmeier

7.1yrs

Tenure

€1,375,000

Compensation

Dr. Hans-Georg Feldmeier is the Chief Executive Officer and Chairman of the Management Board at Dermapharm Holding SE and also serves as Member of the Management Board from August 2017.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Hans-Georg Feldmeier	CEO & Chairman of the Management Board	7.1yrs	€1.38m	no data
Christof Dreibholz	CFO, Chief Compliance Officer & Member of Management Board	1.8yrs	€617.00k	no data
Andreas Eberhorn	Chief Marketing Officer & Member of Management Board	2yrs	€612.00k	no data
Britta Hamberger	Head of Investor Relations & Corporate Communications	no data	no data	no data

2.0yrs

Average Tenure

Experienced Management: 0A5J's management team is considered experienced (2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Lothar Lanz	Independent Member of Supervisory Board	6.7yrs	€80.00k	no data
Wilhelm Beier	Chairman of the Supervisory Board	7.1yrs	€80.00k	no data
Erwin Kern	Independent Vice Chairman of the Supervisory Board	7.1yrs	€80.00k	no data

7.1yrs

Average Tenure

68yo

Average Age

Experienced Board: 0A5J's board of directors are considered experienced (7.1 years average tenure).

Dermapharm Holding Management

Management criteria checks 4/4

Key information

Recent management updates

Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024

Dermapharm Holding SE Announces Executive Changes

Recent updates

Second quarter 2024 earnings released: EPS: €0.32 (vs €0.17 loss in 2Q 2023)

First quarter 2024 earnings released: EPS: €0.81 (vs €0.92 in 1Q 2023)

Dermapharm Holding SE to Report Q1, 2024 Results on May 15, 2024

Full year 2023 earnings released: EPS: €1.16 (vs €2.49 in FY 2022)

Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024

Dividend of €0.88 announced

Dermapharm Holding SE to Report Fiscal Year 2023 Results on Mar 28, 2024

New minor risk - Financial position

Third quarter 2023 earnings released: EPS: €0.46 (vs €0.98 in 3Q 2022)

Now 21% undervalued after recent price drop

Second quarter 2023 earnings released: €0.17 loss per share (vs €0.27 profit in 2Q 2022)

Upcoming dividend of €1.05 per share at 2.3% yield

Full year 2022 earnings released: EPS: €2.49 (vs €3.89 in FY 2021)

Third quarter 2022 earnings released: EPS: €0.98 (vs €1.15 in 3Q 2021)

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: €0.27 (vs €0.74 in 2Q 2021)

Dermapharm Holding SE Announces Executive Changes

Dermapharm Holding SE Provides Earnings Guidance for the Full Year 2022

Upcoming dividend of €2.17 per share

First quarter 2022 earnings released: EPS: €0.69 (vs €0.67 in 1Q 2021)

Dermapharm Holding SE Provides Earnings Guidance for the Full Year 2022

Full year 2021 earnings released: EPS: €3.89 (vs €1.59 in FY 2020)

Dermapharm Holding SE Proposes Dividend for the Year 2021

Investor sentiment deteriorated over the past week

Dermapharm Holding SE (XTRA:DMP) completed the acquisition of C³ - Cannabinoid Compound Company Gmbh from Canopy Growth Corporation (TSX:WEED).

Dermapharm Holding SE (XTRA:DMP) completed the acquisition of C³ - Cannabinoid Compound Company Gmbh from Canopy Growth Corporation (TSX:WEED).

Dermapharm Holding SE (XTRA:DMP) entered into an agreement to acquire C3 - Cannabionoid Compound Company GmbH from Canopy Growth Corporation (TSX:WEED) for approximately €120 million.

Third quarter 2021 earnings released: EPS €1.15 (vs €0.42 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.74 (vs €0.22 in 2Q 2020)

First quarter 2021 earnings released: EPS €0.67 (vs €0.50 in 1Q 2020)

Dermapharm Confirms Earnings Guidance for 2021

Full year 2020 earnings released: EPS €1.59 (vs €1.43 in FY 2019)

Dermapharm Holding SE Provides Revenue Guidance for Fiscal 2021

Investor sentiment improved over the past week

Dermapharm Holding SE Expects the Collaboration with BioNTech SE for the Production of the Covid-19 Vaccine Comirnaty

New 90-day high: €63.75

New 90-day high: €58.25

Market bids up stock over the past week

Revenue misses expectations

Third quarter 2020 earnings released: EPS €0.42

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age